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Abstract 
The crystal structures of 5-(5-furan-2-yl)-2'-deoxyuridine (II), 5-(5-bromofuran-2-yl)-2'-deoxyuridine (IV) and 
5-(3-bromothien-2-yl)-2'-deoxyuridine (V) have been studied in order to explain the different affinity of the 
compounds for the herpes simplex virus type 1 (HSV-1) thymidine kinase. These compounds present a variable 
affinity according to the position of the heteroatom substituting the five-membered ring. An unfavourable 
substitution in the five-membered ring for interaction with the HSV-1 thymidine kinase has been identified. 
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Attempts to identify antiherpes agents by a rational drug design approach have not been very successful till now. 
A number of nucleoside analogues are known to inhibit herpes simplex virus (HSV) replication (De Clercq and 
Torrence, 1978; De Clercq, 1981) but they were discovered by accident. This is partially due to the fact that a 
systematic study of the structure of the targets for the antiviral nucleosides has not been carried out. Also the 
study of the structural requirements of the modified nucleosides for antiherpes activity has not been done 
profoundly. In continuation of our research on the structure/anti-HSV-1 activity relationships of modified 
nucleosides, we studied the structural properties of a new series of 5-heteroaromatic substituted 2'-deoxyuridines. 
The mechanism of action of these modified nucleosides (Derse et al., 1981; De Clercq et al., 1986) involves 
virus-encoded enzymes important in DNA replication, among them thymidine kinase (TK) and DNA 
polymerase. TK catalyses the transfer of the γ-phosphoryl group of ATP to the 5'-OH of thymidine to provide 
dTMP, an important precursor of HSV-1 DNA synthesis. The DNA polymerase catalyses replication of the viral 
genome. The HSV-1 thymidine kinase is particularly tolerant for pyrimidine 2'-deoxynucleosides substituted at 
the 5-position of the base, and many such compounds display antiherpes activity. Their selectivity primarily 
depends upon a preferential activation (phosphorylation) by the HSV-1 encoded TK (Desgranges et al., 1983). 
Next they are converted to their 5'-triphosphate form, interact with virus-specific DNA polymerase and disrupt 
viral replication by inhibiting the polymerase and/or by incorporation into viral DNA (Elion et al., 1977; De 
Clercq et al., 1979; Ruth and Cheng, 1981). The great potential of this class of compounds is demonstrated by 
the clinical use of 5-(2-bromovinyl)-2'-de-oxyuridine (BVDU) which in vitro and in vivo inhibits the replication 
of HSV-1 and varicella zoster virus (VZV). This compound, however, has the disadvantage that it is rapidly 
cleaved by phosphorylases, resulting in formation of the antivirally inactive bromovinyluracil. Phosphorylase 
stable 5-substituted 2'-deoxynu-cleosides might thus have some advantage over BVDU. 
In an effort to try to improve the properties of existing 5-substituted pyrimidine nucleoside analogues   we   have   
synthesized   several   5-heteroaromatic substituted congeners (Wigerinck et al., 1991a; Wigerinck et al., 1991b; 
Wigerinck et al., 1993). Many among them demonstrate potent anti-HSV-1 activity. These active compounds are 
selectively phosphorylated by the viral TK (Bohman et al., 1994). 
Here we report on the structure-TK affinity relationships of 5-(5-furan-2-yl)-2'-deoxyuridine, 5-(5-bromofuran-
2-yl)-2'-deoxyuridine and 5-(3-bromothien-2-yl)-2'-deoxyuridine and compare them with the structural 
properties of 5-(5-thien-2-yl)-2'-deoxyuridine and 5-(5-bromothien-2-yl)-2'-deoxyuridine (Creuven et al., 1995). 
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Fig.  1. I: 5-(5-thien-2-yl)-2'-deoxyuridine. II: 5-(5-furan-2-yl)-2'-deoxyuridine. III: 5-(5-bromothien-2-yl)-2'-
deoxyuridine. IV: 5-(5-bromofuran-2-yl)-2'-deoxyuridine. V: 5-(3-bromothien-2-yl)-2'-deoxyuridine. 
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Table 1: Crystal data for compounds II, IV and V 
 II IV V 
Compound CI3H14N2O6 (C13H13N2O6Br.H2O)2 C13H13N2O5SBr 
Formula weight 294.3 782.4 389.2 
Crystal system Monoclinic monoclinic Hexagonal 
Space group P21 C2 P61 
Cell constants    
    a(Ǻ) 10.352 (3) 21.289 (3) 20.421 (3) 
   b(Ǻ) 20.723 (3) 6.7850 (9) 20.421 (3) 
   c(Ǻ) 6.016 (2) 22.592 (3) 6.487 (4) 
   β(°) 91.131 (13) 113.331 (12) 90.0 (1) 
   γ(°) 90.0 (1) 90.0 (1) 120.0 (1) 
Cell volume (Ǻ3) 1290.23 (8) 2996.5 (8) 2342.8 (36) 
Unit cell 4 2 6 
βcalc (g/cm
3
) 1.515 1.734 1.587 
µcalc (cm
-1
) 1.1 41.3 50.7 
Crystal dimensions (mm) 0.25×0.19×0.17 0.36×0.11×0.07 0.3×0.1×0.13 
Reflections measured 3971 3296 7592 
Reflections observed [F0≥4σ(F0)] 3188 3212 2086 
Rint 0.008 0.022 0.074 
GOF 1.10 1.02 1.09 
R = ∑||F0|-|Fc|/Σ||F0| 0.048 0.034 0.062 
WR
2
 0.106 0.095 0.169 
(Δ/σ)max 0.376 0.26 0.006 
(Δp)min (eǺ
3
) -0.21 -0.72 -0.39 
(Δp)max (eǺ
3
) 0.37 0.41 1.13 
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Table 2 Final atomic coordinates of non-hydrogen atoms and thermal parameters (×10
4
) with E.S.D. values in 
parentheses for 5-(5-furan-2-yl)-2'-deoxyuridine (II) 
Atoms x/a y/b z/c U
a
eq 
O(06) 5401 (3) 148 (2) -1582 (5) 38 (1) 
C(01) 4762 (5) -154(3) -3281 (7) 46 (1) 
C(02) 3487 (5) -60 (3) -3116 (7) 45 (1) 
C(03) 3314 (4) 324 (3) -1240 (7) 40 (1) 
C(04) 4485 (4) 431 (3) -295 (7) 28 (1) 
C(05) 4984 (4) 767 (2) 1648 (7) 27 (1) 
C(06) 4086 (4) 1084 (3) 3161 (6) 28 (1) 
O(01) 2917 (3) 1106(2) 2941 (5) 43 (1) 
N(01) 4688 (3) 1377 4951 (5) 29 (1) 
C(07) 5978 (4) 1406 (3) 5476 (7) 29 (1) 
O(02) 6410 (3) 1689 (2) 7134 (4) 32 (1) 
N(02) 6761 (3) 1106 (2) 3956 (5) 27 (1) 
C(08) 6252 (4) 796 (3) 2118 (7) 31 (1) 
O(03) 8787 (3) 974 (2) 2378 (5) 35 (1) 
C(09) 8183 (4) 1172 (3) 4334 (7) 30 (1) 
C(10) 8715 (4) 744 (3) 6192 (7) 42 (1) 
C(ll) 10086 (4) 644 (3) 5438 (8) 41 (1) 
O(04) 10785 (3) 1195 (3) 6114 (6) 65 (1) 
C(12) 9941 (4) 606 (3) 2902 (8) 40 (1) 
C(13) 9847 (7) -64 (4) 1867 (12) 76(2) 
O(05) 8944 (5) -410 (3) 2877 (11) 101 (3) 
O(26) 3433 (3) 3682 (2) 6303 (5) 42 (1) 
C(21) 3989 (5) 3981 (3) 8143 (7) 47 (1) 
C(22) 5249 (5) 3832 (3) 8329 (8) 43 (1) 
C(23) 5529 (4) 3423 (3) 6511 (8) 38 (1) 
C(24) 4420 (4) 3327 (3) 5314 (7) 31 (1) 
C(25) 4065 (4) 2997 (3) 3298 (7) 31 (1) 
C(26) 5039 (4) 2659 (3) 2116 (7) 32 (1) 
O(21) 6185 (3) 2611 (2) 2635 (5) 42 (1) 
N(21) 4595 (3) 2343 (2) 195 (6) 30 (1) 
C(27) 3378 (4) 2361 (3) -673 (7) 29 (1) 
O(22) 3059 (3) 2075 (2) -2404 (5) 40 (1) 
N(22) 2497 (3) 2720 (2) 469 (6) 29 (1) 
C(28) 2848 (4) 3012 (3) 2451 (7) 28 (1) 
O(23) 682 (3) 3386 (2) 75(5) 32 (1) 
C(29) 1166 (4) 2772 (3) -505 (7) 29 (1) 
C(30) 237 (4) 2269 (3) 360 (8) 38 (1) 
C(31) -1040 (4) 2622 (3) 174 (8) 39 (1) 
O(24) -1563 (3) 2600 (2) -2036 (5) 51 (1) 
C(32) -681 (4) 3326 (3) 658 (8) 39 (1) 
C(33) -833 (5) 3547 (3) 2993 (9) 56 (2) 
O(25) -172 (4) 3157 (3) 4562 (6) 85 (2) 
a(Ueq=1/3SiSjuija*ia*jaiaj) 
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2. Material and methods 
2.1. Compounds 
The compounds used in this study are depicted in Fig.  1. The synthesis of 5-(5-thien-2- yl)-2'-dUrd (I), 5-(5-
furan-2-yl)-2'-dUrd (II), 5-(5-bromothien-2-yl)-2'-dUrd (III), 5-(5-bromo-furan-2-yl)-2'-dUrd (IV) (Wigerinck et 
al., 1991a) and 5-(3-bromothien-2-yl)-2'-dUrd (V) (Luyten et al., 1995) has been described before. Also their 
IC50 for the HSV-1 thymidine kinase is given in Fig. 1. These data were previously published (Bohman et al., 
1994; Luyten et al., 1995). The crystal structure of compounds I and III have been published elsewhere (Creuven 
et al., 1995). 
2.2. X-ray diffraction 
Prismatic colourless crystals were obtained at room temperature by slow evaporation of a methanol solution 
(compound II), of an ethanol solution with a few water drops (compound IV) and of a methanol/acetonitrile 
mixture (compound V). 
Crystal data for compounds II, IV and V are reported in Table 1. The X-ray intensities were collected on a 
graphite-monochromated CAD-4 Enraf-Nonius diffractometer with MoKα radiation (1 = 0.71073) using ω-θ 
scan for compounds II, and with CuKα radiation (Λ= 1.54178) using ω-2θ scan for compounds IV and V. 
Lorentz and polarization corrections were applied for the three data sets, while psi-scan absorption correction 
was applied only for IV (Tmin = 0.300 and Tmax = 0.454). 
The structures were solved by the application of direct methods (SHELXS86 program) (Sheldrick, 1986) and 
refined by full-matrix least squares on F
2
 (SHELXL93) (Sheldrick, 1993). A number of 2989, 3103 and 2220 
reflections were used during subsequent structure refinement for compounds II, IV and V, respectively. Non-
hydrogen atoms were refined anisotropically while H atoms were included but not refined. 
Structure refinement of II, IV and V converged to values of R = 0.048, R = 0.034 and R = 0.062, respectively. 
Note that the intensity data of compound V were collected on the basis of a monoclinic crystal system and were 
treated like a hexagonal system to solve the structure. The final geometrical analysis was performed by the 
PLATON92 program (Spek, 1990) and the representation of crystal packing by the ORTEP program (Johnson, 
1976). 
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Table 3 Final atomic coordinates of non-hydrogen atoms and thermal parameters (× 10
4
) with E.S.D. values in 
parentheses for 5-(5-bromo-furan-2-yl)-2'-deoxyuridine (IV); W stands for the oxygen atom of a water molecule 
Atoms x/a y/b z/c U
a
eq 
Br(01) -4626 (1) 9837 -663 (1) 49(1) 
C(01) -3706 (2) 9983 (8) -127 (2) 35(1) 
C(02) -3370 (2) 10073 (8) 523 (2) 40(1) 
C(03) -2664 (2) 10120 (8) 633 (2) 38(1) 
C(04) -2615 (2) 10069 (7) 56(2) 30(1) 
O(06) -3263 (1) 9992 (6) -425 (1) 34(1) 
C(05) -2067 (2) 10072 (7) -166 (2) 27(1) 
C(06) -1355 (2) 9960 (8) 291 (2) 32(1) 
O(01) -1171 (1) 9948 (7) 881 (1) 47(1) 
N(01) -884 (2) 9908 (7) 23(1) 34(1) 
C(07) -996 (2) 9938 (8) -618 (2) 310) 
O(02) -536 (1) 9836 (8) -810 (1) 45(1) 
N(02) -1678 (2) 10065 (6) -1031 (1) 31(1) 
C(08) -2185 (2) 10148 (7) -802 (2) 30(1) 
O(03) -2180 (1) 12052 (6) -1942 (1) 37(1) 
C(09) ' -1854(2) 10197 (7) -1723 (2) 33(1) 
C(10) -2351 (2) 8648 (8) -2131 (2) 39(1) 
C(ll) -2696 (2) 9689 (9) -2765 (2) 42(1) 
O(04) -2272 (2) 9488 (8) -3115 (1) 57(1) 
C(12) -2728 (2) 11832 (8) -2574 (2) 39(1) 
C(13) -3394(3) 12468 (11) -2548 (2) 58(2) 
O(05) -3571 (2) 11138 (9) -2148 (2) 70(1) 
Br(21) -4052 (1) 7111 (1) -4298 (1) 60(1) 
C(21) -3613 (2) 7173 (9) -4860 (2) 42(1) 
C(22) -3829 (2) 7277 (9) -5505 (2) 48(1) 
C(23) -3231 (2) 7309 (9) -5638 (2) 41 (1) 
C(24) -2687 (2) 7240 (7) -5063 (2) 33(1) 
O(26) -2913 (1) 7156 (6) -4570 (1) 40(1) 
C(25) -1950 (2) 7266 (7) -4847 (2) 31 (1) 
C(26) -1637 (2) 7194 (8) -5311 (2) 34(1) 
O(21) -1942 (2) 7049 (7) -5899 (1) 51 (1) 
N(21) -929 (2) 7231 (7) -5044 (1) 36(1) 
C(27) -506 (2) 7282 (8) -4405 (2) 35(1) 
O(22) 118(1) 7241 (8) -4216 (1) 49(1) 
N(22) -836 (2) 7398 (6) -3989 (1) 32(1) 
C(28) -1543 (2) 7354 (7) -4214 (2) 34(1) 
O(23) -483 (2) 5398 (5) -3082 (1) 42(1) 
C(29) -421 (2) 7336 (8) -3295 (2) 33(1) 
C(30) -614 (2) 8730 (7) -2873 (2) 37(1) 
C(31) -322 (2) 7616 (8) -2233 (2) 34(1) 
O(24) 400 (2) 7905 (8) -1945 (1) 57(1) 
C(32) -476 (2) 5504 (8) -2439 (2) 37(1) 
C(33) -1169 (2) 4772 (10) -2482 (2) 45(1) 
O(25) -1156 (2) 4745 (7) -1846 (2) 54(1) 
W(01) -4596 (4) 7259 (15) -3211 (4) 156 (3) 
W(02) -3868 (6) 7194 (17) -1966 (5) 199 (5) 
a
(Ueq=1/3SiSjuija*ia*jaiaj) 
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Table 4 Final atomic coordinates of non-hydrogen atoms and thermal parameters (× 10
4
) with E.S.D. values in 
parentheses for 5-(4-bromo-thien-2-yl)-2'-deoxyuridine (V) 
Atoms x/a y/b z/c U
a
eq 
Br(01) 1452 (1) 8485 7(2) 76(1) 
S(01) 2916 (1) 10102 (1) -4657 (3) 65(1) 
C(01) 1994 (7) 9618 (6) -5401 (16) 74(3) 
C(02) 1544 (6) 9117 (5) -4019 (17) 77(3) 
C(03) 1955 (5) 9101 (4) -2255 (14) 56(2) 
C(04) 2714 (4) 9610 (4) -2304 (11) 43(2) 
C(05) 3306 (4) 9761 (4) -853 (11) 40(2) 
C(06) 3928 (4) 10528 (4) -587 (11) 44(2) 
O(01) 4041 (4) 11060 (3) -1721 (11) 66 (2) 
N(01) 4410 (4) 10634 (3) 1028 (10) 45(1) 
C(07) 4431 (4) 10092 (4) 2204 (11) 42(2) 
O(02) 4889 (3) 10231 (3) 3568 (9) 56(1) 
N(02) 3859 (3) 9356 (3) 1773 (10) 39(1) 
C(08) 3328 (4) 9217 (3) 274 (11) 38(1) 
O(03) 3482 (3) 8072 (2) 1863 (9) 54(1) 
C(09) 3918 (4) 8755 (4) 2892 (12) 44(2) 
C(10) 3629 (5) 8657 (4) 5049 (14) 57(2) 
C(ll) 2838 (4) 8033 (6) 4873 (15) 70(3) 
O(04) 2571 (4) 7663 (5) 6821 (12) 98 (3) 
C(12) 2920 (6) 7529 (5) 3282 (14) 77(3) 
C(13) 2128 (6) 7107 (6) 2186 (19) 80 (3) 




3.1. X-ray diffraction 
The final atomic coordinates and temperature factors of non-hydrogen atoms are available from the Journal Data 
Bank and given in Table 2, Table 3 and Table 4. The atom numbering and the bond lengths are reported in Fig. 2 
(a, b, c), the valence angle in Fig. 3 (a, b, c). 
Compounds II and IV possess two molecules in the asymmetric unit whereas only one is present in the 
asymmetric unit of compound V. In each compound, crystal packing is assured by hydrogen bonds. Their 
geometrical characteristics are summarized in Table 5. The ordering in the crystal network of compounds II and 
IV is characterized by a parallel arrangement of the planar moieties of the molecules. The short distance between 
the two considered partners (3.5-4.0 Ǻ) allows a π-π interaction which could lead to a charge transfer. 
Compound IV co-crystallizes with two water molecules. The first co-crystallization molecule is involved in 
hydrogen bonds with the bromine atom (Ow1-Br21 distance = 3.105 Ǻ) and with the oxygen atom of the second 
water molecule (Ow1-Ow2: 2.620 Ǻ). This latter equally interacts with the O5 of the ribose moiety (O5-OW2: 2.817 
Ǻ). The parallel ordering is not observed in the crystal network of the compound V on account of its space group 
(P61)∙ 
The two molecules constituting the asymmetric unit of furan-2-yl (II) and bromofuran-2-yl (IV) gather in dimers 
by formation of H bonds between the two uracil rings. N,-O22 and N21-O2 distances are, respectively, 2.752(5) Ǻ, 
2.982(5) Ǻ for compound II. Distance between N1-O2 and N21-O22 for compound IV are 2.836(6) Ǻ and 2.839(6) 
Ǻ (Table 5). On the contrary, compound V describes no hydrogen dimeric bonds. 
X-ray crystal structures of two similar analogues 5-(5-thien-2-yl)-2'-deoxyuridine (I) and 5-(5-bromothien-2-yl)-
2'-deoxyuridine (III), have been previously reported (Creuven et al., 1995). 
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Fig. 2. Atomic numbering and bond lengths (Ǻ) for (a) compound II, (b) compound IV and (c) compound V. Max 
E.S.D. values are 0.007 Ǻ. 
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The observed bond lengths and angles in the three compounds correspond to standard values, except for the C4-




sp bond (1.394 Ǻ). The torsion 
angles (C7-N2-C9-C10) vary from one molecule to another (Table 6). The orientation of the sugar moiety versus 
the uracil ring is variable. The torsion angles C3-C4-C5-C8 (C23-C24-C25-C28) listed in Table 6 reveal a quasi-
coplanar orientation of the uracil group and the five-membered ring with an angle value of about 36°. 
For thienyl analogues (I, III, V), the sulphur atom is located in the vicinity of the carbonyl group of the uracil 
ring. The S1 and O1 atoms participate in an intramolecular interaction (Lozac'h, 1971), leading to the formation 
of 'pseudo-5-membered ring'. The S-O distance (Table 7) is shorter than the van der Waals contacts (3.25 Ǻ). For 
furanyl analogues (II, IV), the substituent in the 5-position is oriented in such a way that the oxygen atoms of the 
uracil moietyand of the furanyl ring are pointed away from each other. Energy calculations (Olivier et al., 1994) 
confirm the favourable crystallographic conformation (about 4.0 kcal/mol) with the sulphur atom (I, III, V) 
located in the neighbourhood of the carbonyl function and the furanyl oxygen atom (II, IV) located at the 
opposite side. 
 




Crystal data of the five deoxyuridine analogues reported here have been compared in order to explain their 
different affinities for the HSV-1 thymidine kinase. 
All molecules have a planar bicyclic conformation. The sulphur atom of the thienyl compounds (I, III, V) is 
positioned in the neighbourhood of the carbonyl group of the uracil moiety. Thus, the sulphur atoms participate 
in an intramolecular contact (S-O interaction) leading to the formation of a 'pseudo-ring'. In contrast, in 
compounds II and IV, the oxygen atom of the carbonyl function interacts with a C-H of the furanyl ring. 
It is clear that the orientation of the heterocyclic moiety in the 5-position depends on the nature of the heteroatom 
(sulphur or oxygen atom). The oxygen of the furanyl ring is pointed in the opposite direction to the sulphur of 
the thienyl ring. However, the difference in orientation could not be the only factor to explain the difference in 
TK affinity of the modified nucleosides as compounds I (thienyl), II (furanyl) and III (5-bromothienyl) show a 
high affinity for the enzyme and IV (bromofuranyl) and V (3-bromothienyl) demonstrate a low affinity for the 
same enzyme. An interesting observation is the fact that, when introducing a bromine sub-stituent in the five 
position of I, a compound (III) is obtained with similar TK affinity. The introduction of a bromine in the five 
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position of II gives a compound (IV) with a lower affinity for the enzyme. As the orientation of the heterocyclic 
moiety does not change, the position of the bromine atom might be crucial. 
In compound III, the S-O intramolecular interaction tends to bring the bromine atom in the upper parts of the 
molecule. Other substituents (chlorine or methyl group) placed in that same position also lead to active 
compounds with the same structural properties: the 5-(5-chlorothien-2-yl)-2'-dUrd (Olivier et al., 1994) and the 
5-(5-methylthien-2-yl)-2'-dUrd (Creuven et al., 1995). If, however, the bromine atom is shifted from C1 to C3 of 
the thienyl ring (V), the affinity for HSV-1 TK decreases (61.4 µM) and the affinity is comparable with the 
affinity of the bromofuranyl congener (IV). 
It thus seems clear that the affinity for the HSV-1 TK can be explained by two structural factors. The nature of 
the heteroatom in the five-membered ring determines the orientation of this ring with respect to the uracil 
moiety. The substituent on the five-membered ring (a bromine atom) creates a steric effect unfavourable for high 
affinity when placed in the lower part of the molecule (in the neighbourhood of the H6 of the uracil ring). Indeed, 
a bromine atom linked to C1 of the furanyl (IV) or to C3 of the thienyl (V) decreases the affinity while the 
affinity is retained when the bromine is placed in the C1 position of the thienyl ring (III). The superposition of 
the three bromine substituted compounds is shown in Fig. 4 (compounds III, IV and V are, respectively, 
represented in dotted, dashed and solid lines) in order to demonstrate the unfavourable zone. This analysis allows 
us to display structural requirements necessary for high affinity against HSV-1 thymidine kinase and might 
therefore contribute to the synthesis of new potent antiviral agents. 
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Fig. 3. Valence angle (°) for (a) compound II, (b) compound IV and (c) compound V. Max E.S.D. values are 
0.4°. 
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Table 5 Hydrogen bonds for compounds II, IV and V 
Compound II     
N-H—O N-H (Ǻ) N—O (Ǻ) H—O (Ǻ) N-H—O(°) 
N(1)i-H(N1)i—O(22)
a
ii 0.864 2.752 (5) 1.899 169.2 
N(21)i-H(N21)i.—O(2)
a
vi 0.982 2.982 (5) 2.015 167.8 
O-H—O O-H (Ǻ) O—O(Ǻ ) H—O (Ǻ) O-H—O(°) 
O(4)i-H(O4)i-O(l)fff 0.902 2.952 (5) 2.125 152.0 
O(5)i-H(O5)i—O(23)iv 1.199 3.091 (7) 2.501 108.1 
O(24),-H(O24)-O(2)v 0.859 2.859 (5) 2.002 175.3 
i = x, y, z iii = 1 + x, y, 2  v = -1+x,y, — \+z  
ii = x, y, z +1 iv= 1—x,y —1/2, -z  υi = x, y, — 1 + x  
Compound IV     
N-H—O N-H (Ǻ) N—O (Ǻ) H—O (Ǻ) N-H—O(°) 
N(1)i-H(N1)i—O(2)
a
ii 0.621 2.836 (6) 2.217 174.5 
N(21)i-H(N21)i—O(22)
a
iii 0.771 2.839 (6) 2.096 162.0 
O-H—O O-H (Ǻ) O—O (Ǻ) H—O (Ǻ) O-H—O(°) 
O(4)i-H(O4)i-O(21)iv 0.847 2.799 (7) 2.032 150.0 
O(5)i-H(O5)i—O(24)v 0.964 2.691 (7) 1.749 164.6 
O(24)i-H(O24)i-O(l)ii 0.812 2.695 (6) 2.080 132.3 
O(5)i-H(O5)i—O(3)vi 1.047 2.788 (7) 1.783 159.2 
O(W1)i-H(OW1)i—O(W2)i 1.038 2.620 (14) 1.591 170.0 
O(5)i-H(O5)i— O(W2)i   2.817  
i = x, y, z Hi = — x, y, —1—z  v= -1/2 + x, l/2+y, z  
ii = —x,y, —z iυ = 1/2 — x, l/2+y, —1—z  υi = x, — 1 +y, z  
Compound V     
O-H—O O-H (Ǻ) O—O (Ǻ) H—O (Ǻ) O-H—O(°) 
O(4)i-H(O4)i—O(1)ii 0.929 2.687 (13) 2.328 102.5 
i = x, y, z ii = y, —x+y, 5/6 + z    
 
a
Hydrogen bonds implicated in dimers. 
Published in Antiviral Research (1996), vol. 30; 63-74 
Status : Postprint (Author’s version) 
 
Table 6: Torsion angle between (a) the five-membered ring and uracil moiety, (b) the uracil and the sugar 
moieties for compounds I-V 
Angles O I II III IV V 
(a) C3-C4-C5-C8 -2.7 (10) -178.5 (7) 7.0 (3) -175.3 (6) 36.2 (14) 
(a) C23-C24-C25-C28 2.6 (9) -177.0 (6) -5.0 (3) 173.9 (6)  
(b) C7-N2-C9-C10 90.6 (7) 76.2 (6) 125.9 (15) 124.9 (5) 80.2 (9) 
(b) C27-N22-C29-C30 121.9 (6) 93.2 (5) 81.6 (17) 138.6 (4)  
 
Table 7: S-O distances (Ǻ) for compounds I, III, V 
Compound S1-O1 S21-O21 
I 2.819 (5) 2.845 (5) 
III 2.834 (13) 2.806 (15) 
V 2.870 (8) — 
 
Fig. 4. View of the superposition of the three bromine substituted compounds (III, IV and V, respectively, 
represented by dotted, dashed and solid lines). The bromine positions that are unfavourable to the interaction of 
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